The antagonistic effect between STAT1 and Survivin and its clinical significance in gastric cancer

Deng,Hao; Zhen,Hongyan; Fu,Zhengqi; Huang,Xuan; Zhou,Hongyan; Liu,Lijiang

doi:10.3892/ol.2011.423

The antagonistic effect between STAT1 and Survivin and its clinical significance in gastric cancer

Authors:
- Hao Deng
- Hongyan Zhen
- Zhengqi Fu
- Xuan Huang
- Hongyan Zhou
- Lijiang Liu
View Affiliations

Affiliations: Department of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, Hubei 430056, P.R. China, JiangDa Pathology Institution, Jianghan University, Wuhan, Hubei 430056, P.R. China
Published online on: September 16, 2011 https://doi.org/10.3892/ol.2011.423
Pages: 193-199

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In previous studies, we observed that STAT1 and Survivin correlated negatively with gastric cancer tissues, and that the functions of the IFN-γ-STAT1 pathway and Survivin in gastric cancer are the same as those reported for other types of cancer. In this study, the SGC7901 gastric cancer cell line and 83 gastric cancer specimens were used to confirm the relationship between STAT1 and Survivin, as well as the clinical significance of this relationship in gastric cancer. IFN-γ and STAT1 and Survivin antisense oligonucleotides (ASONs) were used to knock down the expression in SGC7901 cells. The protein expression of STAT1 and Survivin was tested by immunocytochemical and image analysis methods. A gastric cancer tissue microarray was prepared and tested by immunohistochemical methods. Data were analyzed by the Spearman's rank correlation analysis, the χ2 test and Cox's multivariate regression analysis. Upon knockdown of IFN-γ, STAT1 and Survivin expression by ASON in the SGC7901 cell line, an antagonistic effect was observed between STAT1 and Survivin. In gastric cancer tissues, STAT1 showed a negative correlation with depth of invasion (p<0.05) in gastric cancer tissues exhibiting a negative Survivin protein expression. Furthermore, in tissues exhibiting a negative STAT1 protein expression, Survivin correlated negatively with N stage (p<0.05). Pathological and molecular markers were used to conduct Cox's multivariate regression analysis, and depth of invasion and N stage were found to be prognostic factors (p<0.05). On the other hand, in tissues exhibiting a negative Survivin protein expression, Cox's multivariate regression analysis revealed that the differentiation type and STAT1 protein expression were prognostic factors (p<0.05). There is an antagonistic effect between STAT1 and Survivin in gastric cancer, and this antagonistic effect is of clinical significance in gastric cancer.

View Figures

View References

1	Liu T, Wang XY, Song WJ, Zu CZ and Li Y: Incidence of gastric malignant tumors during the past 20 years in Tianjin. Shijie Huaren Xiaohua ZaZhi. 12:20–22. 2004.
2	Lanwers GY, Scoot GV and Karpeh MS: Immunohistochemical evaluation of bcl-2 protein expression in gastric adenocarcinoma. Cancer. 75:2209–2213. 1995. View Article : Google Scholar : PubMed/NCBI
3	Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998. View Article : Google Scholar : PubMed/NCBI
4	Ambrosini G, Adida C and Altieri D: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
5	Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ and Schreiber RD: Demonstration of an interferon-γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA. 95:7556–7561. 1998.
6	Lee CK, Rao DT, Gertner R, Gimeno R, Frey AB and Levy DE: Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol. 165:3571–3577. 2000. View Article : Google Scholar : PubMed/NCBI
7	Lee CK, Smith E, Gimeno R, Gertner R and Levy DE: STAT1 affects lymphocyte survival and proliferation partially independent of its role downstream of IFN-γ. J Immunol. 164:1286–1292. 2000.PubMed/NCBI
8	Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ and Schreiber RD: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410:1107–1111. 2001. View Article : Google Scholar : PubMed/NCBI
9	Liu KD, Gaffen SL and Goldsmith MA: JAK/STAT signaling by cytokine receptors. Curr Opin Immunol. 10:271–278. 1998. View Article : Google Scholar : PubMed/NCBI
10	Darnell JE Jr, Kerr IM and Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
11	Schindler C and Darnell JE Jr: Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 64:621–651. 1995. View Article : Google Scholar : PubMed/NCBI
12	Dupuis S, Dargemont C, Fieschi C, Thomassin N, Rosenzweig S, Harris J, Holland SM, Schreiber RD and Casanova JL: Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science. 293:300–303. 2001. View Article : Google Scholar : PubMed/NCBI
13	Durbin JE, Hackenmiller R, Simon MC and Levy DE: Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 84:443–450. 1996. View Article : Google Scholar : PubMed/NCBI
14	Bromberg J and Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 19:2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI
15	Ouchi T, Lee SW, Ouchi M, Aaronson SA and Horvath CM: Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-γ target genes. Proc Natl Acad Sci USA. 97:5208–5213. 2000.PubMed/NCBI
16	Chin YE, Kitagawa M, Kuida K, Flavell RA and Fu XY: Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol. 17:5328–5337. 1997.PubMed/NCBI
17	Salvesen GS and Duckett CS: Apoptosis: IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol. 3:401–410. 2002.
18	Srinivasula SM and Ashwell JD: IAPs: what’s in a name? Mol Cell. 30:123–135. 2008.
19	Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003. View Article : Google Scholar : PubMed/NCBI
20	Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008. View Article : Google Scholar : PubMed/NCBI
21	Chandele A, Prasad V, Jagtap JC, Shukla R and Shastry PR: Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia. 6:29–40. 2004. View Article : Google Scholar : PubMed/NCBI
22	Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, Caspases, and anticancer drugs. Cancer Res. 58:5315–5320. 1998.PubMed/NCBI
23	Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, Price J, Chen J, Freeman M and Hallahan DE: Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res. 64:2840–2845. 2004. View Article : Google Scholar : PubMed/NCBI
24	Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK and Oh BH: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochem. 40:1117–1123. 2001. View Article : Google Scholar : PubMed/NCBI
25	Deng H, Zhen HY, Zhou HY, Chen QX and Liu LJ: Role of IFN-γ-STAT1 pathway in human gastric adenocarcinoma. World Chin J Digestol. 17:1103–1107. 2009.
26	Deng H, Wu RL, Chen Y and Liu LJ: STAT1 and Survivin expression in full lymph node examined gastric cancer by using tissue microarray technique. Chin Ger J Clin Oncol. 5:249–252. 2006. View Article : Google Scholar
27	Deng H, Huang X, Gao YJ, Zhen HY and Liu LJ: Regulatory effect of IFN-γ on the survivin signaling pathway in gastric adenocarcinoma. World Chin J Digestol. 18:3249–3253. 2010.
28	Beppu K, Morisaki T, Matsunaga H, Uchiyama A, Ihara E, Hirano K, Kanaide H, Tanaka M and Katano M: Inhibition of interferon-c-activated nuclear factor-κB by cyclosporin A: a possible mechanism for synergistic induction of apoptosis. Biochem Biophys Res Commun. 305:797–805. 2003.
29	Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS and Tweardy DJ: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest. 102:1385–1392. 1998. View Article : Google Scholar : PubMed/NCBI
30	Olie RA, Simões-Wüst AP, Baumann B, Leech SH, Fabbro D, Stahel RA and Zangemeister-Wittke U: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60:2805–2809. 2000.PubMed/NCBI
31	Liu LJ and Zhang YT: The clinical research of lymph node metastasis in gastric cancer. Chin J Exper Surgery. 12:91–92. 1995.
32	Pennati M, Folini M and Zaffaroni N: Targeting survivin in cancer therapy. Expert Opin Ther Targets. 12:463–476. 2008. View Article : Google Scholar
33	Altieri DC: Survivin and IAP proteins in cell-death mechanisms. Biochem J. 430:199–205. 2010. View Article : Google Scholar : PubMed/NCBI
34	Lee J, Kang WK, Park JO, et al: Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. Acta Pathol Microbiol Immunol Scand Suppl. 117:598–606. 2009. View Article : Google Scholar : PubMed/NCBI
35	Li Y, Han J, Wang LF, Lin SX, Yao LB, Yu Q and Liu XP: Characteristics of anoikis resistance of human gastric cancer cell lines. J Fourth Mil Med Univ. 24:485–488. 2003.